NASDAQ 100 % ()
FTSE 100 % ()
S&P 500 % ()
BTC/USD % ()
XRP/USD % ()
ETH/USD % ()
GBP/USD % ()
GOLD % ()
SILVER % ()

SNSS

Sunesis Pharmaceuticals Inc. NASDAQ Capital Market
$4.98
Open: $0.00 High: $0.00 Low: $0.00 Close: $0.00
Range: 0 - 0
Volume: 0
Market: Extended-hours
Powered by Finage Stock APIDelayed data
SNSS
Sunesis Pharmaceuticals Inc. 395 Oyster Point Boulevard South San Francisco CA, 94080 http://www.sunesis.com
Sunesis Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers.
  • CEO: Dayton Misfeldt
  • Employees: 34
  • Sector: Healthcare
  • Industry: Biotechnology
SNSS News
Latest news about the SNSS
  • Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and $65M Private Placement

    Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the closing of its merger with Sunesis Pharmaceuticals, Inc. (previously trading on Nasdaq under "SNSS"). The combined, publicly traded company will focus on the advancement and expansion of Viracta's clinical stage pipeline, including Viracta's lead program for the treatment of Epstein-Barr virus (EBV)-positive lymphoma. Shares of the combined company, which is operating under the name Viracta Therapeutics, Inc., will commence trading on the Nasdaq Global Select Market under the ticker symbol "VIRX" on February 25, 2021.

    View More →
  • Sunesis Pharma Climbs After Viracta Poised To Nab US Patent For Nanatinostat/Valganciclovir Regime

    Sunesis Pharmaceuticals Inc (NASDAQ: SNSS) merger partner, Viracta Therapeutics Inc announces that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No. 16/924,082, titled "Methods of Treating Virally Associated Cancers with Histone Deacetylase Inhibitors," related to the use of Viracta's oral combination product candidate of nanatinostat and valganciclovir. The allowed claims cover the anticipated dose regimen to be advanced in the planned global registration trial to treat Epstein-Barr virus (EBV)-associated lymphoma and other lymphoproliferative disorders. Upon its grant, the resulting patent will provide protection into at least 2040. In November last year, Sunesis Pharmaceuticals announced to merge with Viracta Therapeutics in an all-stock deal. Price Action: SNSS gained 5.5% at $3.49 in market trading hours on the last check Tuesday. See more from BenzingaClick here for options trades from BenzingaAddex Therapeutics' GABAB PAM Candidate Shows Potential For Alcohol Use DisorderWindtree Therapeutics' AEROSURF Drug Delivery Device Secures US Patent© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →
  • Viracta Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering the Use of its Combination Product Candidate for the Treatment of Epstein-Barr Virus-associated Lymphoma

    Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No. 16/924,082. The allowed application, titled "Methods of Treating Virally Associated Cancers with Histone Deacetylase Inhibitors," describes the use of Viracta's all-oral combination product candidate of nanatinostat, the Company's proprietary investigational drug, and valganciclovir. The allowed claims cover the anticipated dose regimen to be advanced in the planned global registration trial for the treatment of Epstein-Barr virus (EBV)-associated lymphoma and other lymphoproliferative disorders. Upon its grant, the resulting patent will provide protection into at least 2040.

    View More →
  • Viracta Therapeutics to Participate in Upcoming Virtual Investor Conferences

    Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that the Company will participate in the upcoming LifeSci Partners Precision Oncology Day on February 17, 2021 and the 10th Annual SVB Leerink Global Healthcare Conference taking place February 22-26, 2021. The Company will present and participate in one-on-one investor meetings at both conferences.

    View More →
  • MERGER INVESTIGATION: Halper Sadeh LLP Investigates CPAH, HMSY, SNSS, EIDX; Shareholders Are Encouraged to Contact the Firm

    NEW YORK, NY / ACCESSWIRE / January 8, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:CounterPath Corporation (NASDAQ:CPAH) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Alianza, Inc. If you are a CounterPath shareholder, click here to learn more about your rights and options.

    View More →
  • SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of SNSS, LOAC, FBSS, and CPAH Mergers

    WILMINGTON, Del., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating: Sunesis Pharmaceuticals, Inc. (NASDAQ CM: SNSS) regarding possible breaches of fiduciary duties and other violations of law related to Sunesis’ agreement to merge with Viracta. Under the terms of the agreement, Sunesis will issue a number of shares of Sunesis common stock to shareholders of Viracta. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-sunesis-pharmaceuticals-inc.Longevity Acquisition Corporation (NASDAQ GS: LOAC) regarding possible breaches of fiduciary duties and other violations of law related to Longevity’s agreement to merge with 4D Pharma PLC. Under the terms of the agreement, Longevity’s shareholders will receive 7.5315 ordinary shares of 4D Pharma per share. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-longevity-acquisition-corporation.Fauquier Bankshares, Inc. (NASDAQ GS: FBSS) regarding possible breaches of fiduciary duties and other violations of law related to Fauquier’s agreement to be acquired by Virginia National Bankshares Corporation. Under the terms of the agreement, Fauquier’s shareholders will 0.6750 shares of Virginia National common stock per share. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-fauquier-bankshares-inc.CounterPath Corporation (NASDAQ CM: CPAH) regarding possible breaches of fiduciary duties and other violations of law related to CounterPath’s agreement to be acquired by Alianza, Inc. Under the terms of the agreement CounterPath’s shareholders will receive $3.49 per share in cash. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-counterpath-corporation.You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or info@rl-legal.com.Rigrodsky & Long, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.Attorney advertising.  Prior results do not guarantee a similar outcome.CONTACT:         Rigrodsky & Long, P.A. Seth D. Rigrodsky Gina M. Serra (888) 969-4242 (Toll Free) (302) 295-5310 Fax: (302) 654-7530 info@rl-legal.com https://rl-legal.com

    View More →
  • ALERT: Halper Sadeh LLP Investigates TDY, TCP, BEAT, HCAP, SNSS; Shareholders Are Encouraged to Contact the Firm

    Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

    View More →
  • SHAREHOLDER ALERT: WeissLaw LLP Reminds HLIX, XLNX, SNSS, and AKER Shareholders About Its Ongoing Investigations

    If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:

    View More →
  • SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Mergers - PNM, TNAV, SNSS, ZAGG, ELY

    Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

    View More →
  • SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of UROV, SNSS, TCF, and PS Mergers

    WILMINGTON, Del., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating: Urovant Sciences Ltd. (NASDAQ GS: UROV) regarding possible breaches of fiduciary duties and other violations of law related to Urovant’s agreement to be acquired by Sumitovant Biopharma Ltd. Under the terms of the agreement Urovant’s shareholders will receive $16.25 per share in cash. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-urovant-sciences-ltd.Sunesis Pharmaceuticals, Inc. (NASDAQ CM: SNSS) regarding possible breaches of fiduciary duties and other violations of law related to Sunesis’ agreement to merge with Viracta. Under the terms of the agreement, Sunesis will issue a number of shares of Sunesis common stock to shareholders of Viracta. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-sunesis-pharmaceuticals-inc.TCF Financial Corporation (NASDAQ GS: TCF) regarding possible breaches of fiduciary duties and other violations of law related to TCF Financial’s agreement to be acquired by Huntington Bancshares Incorporated. Under the terms of the agreement, TCF Financial’s shareholders will receive 3.0028 shares of Huntington Bancshares per share. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-tcf-financial-corporation-merger.Pluralsight, Inc. (NASDAQ GS: PS) regarding possible breaches of fiduciary duties and other violations of law related to Pluralsight’s agreement to be acquired by affiliates of Vista Equity Partners VII, L.P. Under the terms of the agreement, Pluralsight’s shareholders will receive $20.26 in cash per share. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-pluralsight-inc-merger.You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or info@rl-legal.com.Rigrodsky & Long, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.Attorney advertising. Prior results do not guarantee a similar outcome.CONTACT:Rigrodsky & Long, P.A. Seth D. Rigrodsky Gina M. Serra (888) 969-4242 (Toll Free) (302) 295-5310 Fax: (302) 654-7530 info@rl-legal.com https://rl-legal.com

    View More →
  • SUNESIS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Sunesis Pharmaceuticals, Inc. - SNSS

    Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed merger of Sunesis Pharmaceuticals, Inc. (NasdaqGS: SNSS) with Viracta Therapeutics, Inc. pursuant to which Sunesis shareholders will end up owning just 14% of the combined company, subject to adjustment. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.

    View More →
  • SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Companies - AKER, INFO, SNSS, WORK, WDR

    Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

    View More →
  • SHAREHOLDER ALERT: WeissLaw LLP Reminds NGA, FIII, and SNSS Shareholders About Its Ongoing Investigations

    If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:

    View More →
  • SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of INFO, SNSS, INSU, and FBSS Mergers

    WILMINGTON, Del., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating: IHS Markit Ltd. (NYSE: INFO) regarding possible breaches of fiduciary duties and other violations of law related to IHS Markit’s agreement to be acquired by S&P Global Inc. Under the terms of the agreement, IHS Markit’s shareholders will receive 0.2838 shares of S&P common stock per share. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-ihs-markit-ltd.Sunesis Pharmaceuticals, Inc. (NASDAQ CM: SNSS) regarding possible breaches of fiduciary duties and other violations of law related to Sunesis’ agreement to merge with Viracta. Under the terms of the agreement, Sunesis will issue a number of shares of Sunesis common stock to shareholders of Viracta. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-sunesis-pharmaceuticals-inc.INSU Acquisition Corp. II (NASDAQ GS: INAQ) regarding possible breaches of fiduciary duties and other violations of law related to INSU Acquisition’s agreement to merge with MetroMile, Inc. Under the terms of the agreement, INSU Acquisition will issue an amount in cash and a number of shares of INSU Acquisition’s Class A common stock to shareholders of MetroMile. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-insu-acquisition-corp-ii.Fauquier Bankshares, Inc. (NASDAQ GS: FBSS) regarding possible breaches of fiduciary duties and other violations of law related to Fauquier’s agreement to be acquired by Virginia National Bankshares Corporation. Under the terms of the agreement, Fauquier’s shareholders will 0.6750 shares of Virginia National common stock per share. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-fauquier-bankshares-inc.You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or info@rl-legal.com.Rigrodsky & Long, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.Attorney advertising.  Prior results do not guarantee a similar outcome.CONTACT:         Rigrodsky & Long, P.A. Seth D. Rigrodsky Gina M. Serra (888) 969-4242 (Toll Free) (302) 295-5310 Fax: (302) 654-7530 info@rl-legal.com https://rl-legal.com

    View More →
  • INVESTIGATION ALERT: Halper Sadeh LLP Continues to Investigate the Following Companies; Shareholders are Encouraged to Contact the Firm – SNSS, WORK, WDR, ANH

    NEW YORK, Dec. 12, 2020 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with Viracta Therapeutics, Inc. Under the terms of the merger agreement, Viracta stockholders will receive shares of newly issued Sunesis common stock. Sunesis stockholders are expected to own approximately 14% of the combined company on a fully diluted basis. If you are a Sunesis shareholder, click here to learn more about your rights and options.Slack Technologies, Inc. (NYSE: WORK) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to salesforce.com, inc. Under the terms of the merger agreement, Slack shareholders will receive $26.79 in cash and 0.0776 shares of salesforce common stock for each Slack share. If you are a Slack shareholder, click here to learn more about their legal rights and options.Waddell & Reed Financial, Inc. (NYSE: WDR) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Macquarie Asset Management for $25.00 per share. If you are a Waddell shareholder, click here to learn more about your rights and options.Anworth Mortgage Asset Corporation (NYSE: ANH) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Ready Capital Corporation. Under the terms of the merger agreement, each share of Anworth common stock will be converted into 0.1688 shares of Ready Capital common stock and $0.61 of cash consideration. If you are an Anworth shareholder, click here to learn more about your rights and options.Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@halpersadeh.com or zhalper@halpersadeh.com.Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.Attorney Advertising. Prior results do not guarantee a similar outcome.Contact Information: Halper Sadeh LLP Daniel Sadeh, Esq. Zachary Halper, Esq. (212) 763-0060 sadeh@halpersadeh.com zhalper@halpersadeh.com

    View More →
  • SHAREHOLDER ALERT: WeissLaw LLP Reminds CLCT, SNSS, WTRE, and STPK Shareholders About Its Ongoing Investigations

    If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:

    View More →
  • Viracta Therapeutics Announces Presentation of Updated Phase 2 Data at ASH 2020 and Productive Outcome of its Recent End of Phase 2 Meeting with the FDA

    Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced recent clinical and regulatory developments regarding its lead program for the treatment of relapsed/refractory (R/R) EBV+ lymphomas.

    View More →
  • ALERT: Halper Sadeh LLP Encourages INFO, SNSS, and WORK Shareholders to Contact the Firm

    NEW YORK, NY / ACCESSWIRE / December 5, 2020 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following mergers:IHS Markit Ltd.

    View More →
  • SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Sunesis Pharmaceuticals, Inc. - SNSS

    Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Sunesis Pharmaceuticals, Inc. ("SNSS" or the "Company") (SNSS) relating to its proposed merger with Viracta Therapeutics, Inc. ("Viracta"). Under the terms of the agreement, Sunesis shareholders will only 14% of the combined company, with Viracta owning the other 86%.

    View More →
  • Lifshitz Law Firm, P.C. Announces Investigation of CLCT, FBM, SNSS and WORK

    NEW YORK, NY / ACCESSWIRE / December 3, 2020 / Collectors Universe, Inc.

    View More →